Download Bibliografía

Bibliografía
Aarons L. (1991). Population pharmacokinetics: theory and practice. Br J clin
Pharmacol, 32: 669-670.
Aiache J.M. (1983). Devissaguet, J.P.; Guyton-Hermmann, A.M. “Biofarmacia”. Ed. El
Manual Moderno. Méjico.
Alberti P.W. (1995) The anatomy and physiology of the ear and hearing. En:
Consultation on Evaluation and Control of Noise Exposure in the Work Environment. WHO,
Geneva, 25-5 Sept 1995.www.who.int/occupational_health/publications/noise2.pdf
Alberti P.W. (1995) The patophysiology of the ear. En: Consultation on Evaluation and
Control of Noise Exposure in the Work Environment. WHO, Geneva, 25-5 Sept
1995.www.who.int/occupational_health/publications/noise3.pdf
Anderson B.J. y Holford N.H.G. (2008). Mechanism-based Concepts of Size and
Maturity in Pharmacokinetics. Annual Reviews of Pharmacology and Toxicology, 48: 303-332.
Audi, S. H., Dawson, C. A., Linehan, J. H., Krenz, G. S., Ahlf, S. B., and Roerig, D. L.
(1998). Pulmonary disposition of lipophilic amine compounds in the isolated perfused rabbit
lung, J Appl Physiol 84: 516-530.
Avis, E., Lieberman H.A., Lachman L. (1992). Pharmaceutical Dosage Forms:
Parenteral Medications. Vol. 1, 2ª ed. Marcel Dekker. Nueva York.
Bartelink IH, Rademarker CMA, Schobben AFAM y col. (2006). Guidelines on
paediatric dosing on the basis of developmental physiology and pharmacokinetic considerations.
Clinical Pharmacokinetics 45(11): 1077-97.
Bassett, D. J. P., and Roth, R. A. (1992). The isolated perfused lung preparation. In: In
vitro methods of toxicology, Watson, R. R., ed. (Boca Raton, Florida, CRC Press), pp. 143-155.
Berg, M. M., Kim, K. J., Lubman, R. L., and Crandall, E. D. (1989). Hydrophilic solute
transport across rat alveolar epithelium, J Appl Physiol 66: 2320-7.
Berkovic SF. (2005). Treatment with anti-epileptic drugs. Australian Family Physician,
34(12):1017-20.
Birkett D.J. (2002). “Farmacocinética no lineal”. En: Birkett DJ.; Farmacocinética
fácil. Revisado: McGraw-Hill. Interamericana. Madrid.
Bisgaard, H.; O'Callaghan,C.; Smaldone, Editors. (2002). “Drug Delivery to the Lung”.
Marcel Dekker publisher. New York.
Bistrian B.R., Walker-Smith J.A. (1999). Inflamatory Bowel Diseases. Nestec Ltd. And
S. Karger A.G. Basel (Suiza).
Björkman, S., Russell Wada D.,Berling, B. M. et al. (2001). Prediction of the
disposition of midazolam in surgical patients by a physiologically based pharmacokinetic
model. Journal of Pharmaceutical Sciences 90: 1226-1241.
Blesch, K.S., Gieschke, R., Tsukamoto, T. (2003). Clinical pharmacokinetic/
pharmacodynamic and physiologically based pharmacokinetic modelling in new drug
development. Investig New Drugs; 21.195-223
Bonate, P.L. (2006). Pharmacokinetic-pharmacodyanmic modelling and simulation.
Springer. New York.
Borchard, G., Cassará, M. L., Roemelé, P. E. H., Florea, B. I., y Junginger, H. E.
(2002). Transport and local metabolism of budesonide and fluticasone propionate in human
bronchial epithelial cell line (Calu-3), J Pharm Sci 91: 1561-1567(2002).
Borrás Almenar, C., Pérez Peiró, C. (2006) “Identificación de pacientes con
oportunidades de mejora de la farmacoterapia”. En: Jiménez Torres, N.V., ed. Borràs Almenar,
C., Climente Martí, M., Merino Sanjuán, M., coeds. Calidad Farmacoterapéutica. Valencia:
Universidad de Valencia.
1
TRATADO GENERAL DE BIOFARMACIA Y FARMACOCINÉTICA. VOLUMEN II
Boxenbaum, H. (1982). Interspecies Scaling, Allometry, Physiological Time and the
Ground Plan of Pharmacokinetics. Journal of Pharmacokinetics and Biopharmaceutics 10:
201-226.
Boxenbaum, H. y Fertig J.B. (1984). Scaling of antipyrine intrinsic clearance of
unbound drug in 15 mammalian species. European Journal of Drug Metabolism and
Pharmacokinetics 9: 177-183.
Bressler, R., Bahl, J.J., (2003). Principles of Drug Therapy for the Elderly Patient. Mayo
Clin Proc, 78: 1564-77.
Brockmoller, J., Tzvetkov, M.V. (2008). Pharmacogenetics:data,concepts and tools to
improve drug discovery and drug treatment. Eur J Clin Pharmacol, 64: 133-57.
Brown, R. A., y Schanker, L. S. (1983). Absorption of aerosolized drugs from the rat
lung, Drug Metab Dispos 11: 355-360.
Burton, M.E., Shaw, L.M., Schentag, J.J., Evans, W. (2006). Applied Pharmacokinetics
& Pharmacodynamics. Principles of Therapeutic Drug Monitoring. 4th ed. Lippincott Willians
& Wilkins. Philadelphia.
Caldés, A., Colom, H., Armendariz, Y., Garrido, M.J., Troconiz, I., Gil-Vernet, S.,
Lloberas, N., Pou, L., Peraire, C. y Grinyó, J.M. (2009). Population Pharmacokinetics of
Ganciclovir after Intravenous Ganciclovir and Oral Valganciclovir Administration in Solid
Organ Transplant Patients Infected with Cytomegalovirus. Antimicrobial Agents and
Chemotherapy, 53(11): 4816-4824,
Calvo, M.V., García, M.J., Lanao, J.M. y Fernández de Gatta, M.M. (2002).
Farmacocinética clínica. Capítulo 2.12 págs: 625-65 En: Farmacia Hospitalaria. 3ª Edición.
Edita Fundación Española de Farmacia Hospitalaria.
Cassidy, J., Berner, B., Chan, K. et al. (1993) Human transbuccal absorption of
diclofenac sodium from a prototype hydrogel delivery device. Pharm Res; 10(1): 126-129.
ChangLai, S. P., Hung, W. T., y Liao, K. K. (1999). Detecting alveolar epithelial injury
following volatile anesthetics by 99mTc DTPA radioaerosol inhalation lung scan, Respiration 66:
506-510.
Chasseaud, L.F. (1993). Role of toxicokinetics in toxicity testing. In: Drug
Toxicokinetics. PG Welling and FA de la Iglesia (eds). Marcel Dekker, New York. pp. 105-142
Conhaim, R. L., Eaton, A., Staub, N. C., y Heath, T. D. (1988). Equivalent pore
estimate for the alveolar-airway barrier in isolated dog lung, J Appl Physiol 64: 1134-1142.
Conhaim, R. L., Watson, K. E., Lai-Fook, S. J., y Harms, B. A. (2001). Transport
properties of alveolar epithelium measured by molecular hetastarch absorption in isolated rat
lungs, J Appl Physiol 91: 1730-1740.
Cordingley, J.L. (1972). “Pores of Kohn”. Thorax 27(4): 433-441.
Crandall, E. D., y Matthay, M. A. (2001). Alveolar epithelial transport, Am J Respir Crit
Care Med 162: 1021-1029.
Dain, J.G., Jaffe, J.M. (1988). Effect of diet and gavage on the absorption and
metabolism of fluperlapine in the rat. Drug Metab Disposition 1988; 16: 238-242.
Dixit, R. y Ward, P. (2007). Use of classical pharmacokinetic evaluations in drug
development and safety assessment. En: Lipscomb JC., Ohanian EV; Toxicokinetics and Risk
Assessment. Informa Healthcare. Nueva York.
Dodoo, A. N. O., Bansa, S., Barlow, D. J., Bennet, F. C., Hider, R. C., Lansley, A. B.,
Lawrence, M. J., y Marriot, C. (2000b). Systematic investigations of the influence of molecular
structure in the transport of peptides across cultured alveolar cell monolayers, Pharm Res 17: 714 (2000b).
Ducongé, J., Fernández-Sánchez, E., Álvarez, D. (2004). Interspecies scaling of the
Monoclonal Anti-EGF Receptor ior EGF/r3 Antibody Disposition using Allometric Paradigm:
is it really suitable? Biopharmaceutics and Drug Disposition 25: 177-186.
Edginton A.N, Schmitt W. y Willmann S. (2006). Development and Evaluation of a
Generic Physiologically Base pharmacokinetic model for children Clin Pharmacokinet 45(10):
1013-1034.
Effros, R.M., Mason, G.R. (1983). Measurements of pulmonary epithelial permeability
in vivo. Am.Rev.Resp.Disp., 127:S59-S65.
2
BIBLIOGRAFÍA
EMEA. CPMP/EWP/280/96. Modified release oral and transdermal dosage forms:
section II (PK and clinical evaluation)
EMEA. CPMP/QWP/604/96. Modified release oral and transdermal dosage forms:
Section I (Quality of modified release products).
Emslie-Smith D. et al. (1988). Texbook of Physiology. 11th Edition. Churchill
Livingston. Edimburgo.
Enna, S. J., y Schanker, L. S. (1973). Phenol red absorption from the rat lung: evidence
of carrier transport, Life Sci 12: 231-239.
Ensom, M.H., Chang, T.K., Patel, P. (2001) Pharmacogenetics: the therapeutic drug
monitoring of the future? Clin Pharmacokinet; 40: 783-802
Ensom, M.H.H., Davis, G.A., Cropp, C.D., Ensom, R.J. (1998). Clinical
pharmacokinetics in the 21 st century. Does the evidence support definitive outcomes? Clin
pharmacokinet, 34: 265-279.
Esteban A., Ruiz Santana S., Grau. (1994). Alimentación enteral en el paciente grave.
Ed. Espringer-Verlag Ibérica S.A. Barcelona.
Ette, E.I. y Willimas, P.J. (2004). Population pharmacokinetics I: Background,
concepts, and models. The Annals of Pharmacotherapy, 38: 1702-1706.
Ette, E.I. (2007). Pharmacometrics. The science of Quantitative Pharmacology. John
Wiley. New Jersey.
European medicines agency, Committee for medicinal products for human use. (2007).
Guideline on reporting the results of population pharmacokinetic analyses. URL:
http://www.ema.europe.eu.
Fagiolino, P., Eiraldi, R., Vázquez, M. (2006). The Influence of Cardiovascular
Physiology on Dose/Pharmacokinetic and Pharmacokinetic/ Pharmacodynamic Relationships.
Clin Pharmacokinet, 45(5):433-48.
Farmacopea Europea 6.ª edición. The European Pharmacopoeia. Bruselas.
Fernández-Candil, J., Gambús, P.L., Trocóniz, I.F., Valero, R., Carrero, E., Bueno, L.,
Fábregas, N. (2008). Pharmacokinetic-pharmacodynamic modeling of the influence of chronic
phenytoin therapy on the rocuronium bromide response in patients undergoing brain surgery.
Eur J Clin Pharmacol; 64: 795-806.
Florence, A.T., Attwood, D. (1991). Physicochemical Principles of Pharmacy. Second
edition. The MacMillan Press Ltd. Londres.
Gabardi, S., Abramson, S. (2005). Drug dosing in chronic kidney disease. Med Clin
North Am, 89:649-87.
Gibaldi, M. (1991). Biopharmaceutics and Clinical Pharmacokinetics, 4ª ed. Lea &
Febiger. Malvern.
Ginsberg, G., Hattis, D., Sonawane, B. et al. (2002). Evaluation of Child/Adult
pharmacokinetic differences from a database derived from therapeutic drug literature.
Toxicological Sciences, 66: 185-200.
Gizurarson, S. (1990). “Animal models for intranasal drug delivery studies. A review
article” Acta Pharm. Nord.; 2(2): 105.
Gizurarson, S. (1993). “The relevance of nasal physiology to the design of drug
absorption studies”. Adv Drug Deliv Rev; 11:329-347.
Goswani, T., Jasti B., Li X. (2008). “Sublingual drug delivery” Critical Reviews in
Therapeutic Drug Carrier Systems 25(5): 449-484.
Groneberg, D. A., Eynott, P. R., Döring, F., Thai Dinh, Q., Oates, T., Barnes, P. J.,
Chung, K.F., Daniel, H. y Fischer, A. (2002). Distribution and function of the peptide
transporter PEPT2 in normal and cystic fibrosis human lung, Thorax 57: 55-60.
Gross, A.S. (2001) “Best practice in therapeutic drug monitoring”. British Journal of
Clinical Pharmacology 52, S1:5-9.
Gumbleton, M., (2001). “Caveolae as potenitial macromolecule trafficking
compartments within alveolar epithelium”, Adv Drug Deliv Rev 49: 61-300.
Guy, R., Hadgraft, J. (1983). “Physicochemical interpretation of the pharmacokinetics
of percutaneous absorption”. J Pharmacokinet Biopharm, 11(2):189-203.
3
TRATADO GENERAL DE BIOFARMACIA Y FARMACOCINÉTICA. VOLUMEN II
Hanley, M.J., Abernethy, D.R., Greenblatt, D.J. (2010). “Effect of obesity on the
pharmacokinetics of drugs in humans”. Clin Pharmacokinet, 49(2): 71-87.
Hashida, M., Okamoto, J., Sezaki, H. (1988) Analysis of drug penetration skin
considering donor concentration decrease. J Pharmacobio-Dyn, 11: 636-44.
Hassan, Y., Al-Ramahi, R., Abd Aziz, N. et al. (2009). Drug Use and Dosing in Chronic
Kidney Disease. Ann Acad Med Singapore, 38(12):1095-103.
Hills, B. A., Butler, B.D. y Lichtenberger, L.M. (1983): “Gastric mucosal barrier:
hydrophobic lining to the lumen of stomach”. Amer. J. Physiol., 14: G561-G568.
Holford, N.H. (2001) “Target concentration intervention: beyond Y2K” British Journal
of Clinical Pharmacology, 52, S1:55-59.
Hooker, A.C., Staatz, C.E., Karlsson, M.O. (2007). Conditional weighted residuals
(CWRES): a model diagnostic for the FOCE method. Pharm Res; 24 (12): 2187-2197.
Houston, J.B. y Wood, S.G. (1983). “Gastrointestinal absorption of drugs an other
xenobiotics”. En: Progress in Drug Metabolism, Vol. 4. Wiley. Nueva York: 57.
Hsieh, D.S. (ed.). (1994). Drug Permeation Enhancement. Marcel Dekker, Inc. New
York.
Hu, T., Hayton, W.L. (2001). Allometric Scaling of Xenobiotic Clerance: Uncertainty
versus Universality. AAPS Pharm Sci 1-14.
Huang, C.H.; Kimura, R.; Nassar, R.B., y Hussain, A. (1985) “Mechanism of Nasal
Absorption of Drugs I: Physicochemical Parameters Influencing the rate of In situ Nasal
Absorption of Drugs in Rats”. J. Pharm. Sci.; 74(6): 608.
ICH M3(R2). (2009). Guidance on Non-Clinical safety studies for the conduct of
human clinical trials and marketing authorization for pharmaceuticals. CPMP/ICH/286/95.
ICH S3A. (1995). Note for guidance on toxicokinetics: The assessment of systemic
exposure in toxicity studies. CPMP/ICH/384/95.
Ito, S., Lee, A. (2003). Drug excretion into breast milk–Overview. Advanced Drug
Delivery Reviews, 55: 617-27.
Jiménez Torres, N.V., Merino Sanjuán, M., Porta Oltra, B. (2008). “Interrelaciones
farmacocinéticas y farmacodinámicas en el paciente subsidiario de soporte nutricional”. Págs:
17-30. En: Interrelación entre fármacos y nutrientes en situaciones fisiopatológicas
determinadas. Editorial Glosa, SL. Barcelona (España).
Jiménez Torres, N.V., Merino Sanjuán, M., Ordovas Bainés, J.P., Casabó Alós, V.G.
(1999). Interacciones entre medicamentos y alimentos: bases farmacoterapéuticas (1ª ed.),
Convaser C.E.E, Valencia.
Jiménez Torres, N.V. (2007). “Interacciones fármaco alimento en oncología”
Comunicación gráfica. Valencia.
Jones, H.M., Parrot, N., Jorga K. et al. (2006). A novel strategy for physiologically
based predictions of human pharmacokinetics. Clinical Pharmacolinetics, 45(5): 511-142.
Jonson, E.N., Karlsson, M.O. (1998). “Automated covariate model building within
NONMEM”. Pharm Res 15: 1463-1468.
Jonson, E.N., Karlsson, M.O. (1999). “Xpose- an S-PLUS based population
pharmacokinetic/pharmacodynamic model building aid for NONMEM”. Comput Methods
Programs Biomed 58: 51-64 .
Karlsson, M.O., Holford, N.H. (2008) .A Tutorial on Visual Predictive Checks. PAGE
17 (2008) Abstr 1434 [www.page-meeting.org/?abstract=1434].
Karlsson, M.O., Jonson, E.N., Wiltse, C.G., Wade, J.R. (1998). “Assumption testing in
population pharmacokinetic models: illustrated with an análisis of moxonidine data from
congestive heart failure”. J Pharmacokin Biopharm 26: 207-246.
Karlsson, M.O., Savic, R.M. (2007). Diagnosing Model Diagnostics. Clinical
Pharmacology & Therapeutics. Vol. 82 (1): 17-20.
Karlsson, M.O., Sheiner, L.B. (1993). “The importance of modeling interoccasion
variability in population pharmacokinetic analyses”. J Pharmacokinet Biopharm. 21: 735-750.
Keshary, P.R., Chien, Y.W. (1984) “Mechanism of transdermal controlled Nitroglycerin
administration (I) Development of a finite dosing skin permeation system”. Drug Delivery Ind
Pharm, 10(6): 883-913
4
BIBLIOGRAFÍA
Kirchheiner, J., Brosen, K., Dhal, M.L. et al. (2001). ”CYP2D6 and CYP2C19
genotype-basd dose recommendations for antidepressants: a first step towards subpopulationspecific dosages”. Acta Psychiatr Scand, 104: 173-92.
Knibbe, C.A., Zuideveld, K.P. et al. (2005). Allometric relationships between the
pharmacokinetics of propofol in rats, children and adults. British Journal of Clinical
Pharmacology 59: 705-711.
Krondahl, E., Tronde, A., Eirefelt, S., Forsmo-Bruce, H., Ekström, G., Hultkvist
Bengtsson, U., y Lennernäs, H. (2002). Regional differences in bioavailability of an opioid
tetrapeptide agonist in vivo in rats after administration to the respiratory tract., Peptides 23:
479-488.
Kulenkampff, H. (1975). “The structural basis of intestinal absorption”, en:
Pharmacology of intestinal absorption: gastrointestinal absorption of drugs. Pergamon, Nueva
York: 1.
Labiris, N. R.; Dolovich, M. B. (2003) “Pulmonary drug delivery. Part I: Physiological
factors affecting therapeutic effectiveness of aerosolized medications” J Clin Pharmacol 56:
588-599.
Lagneau, F., Marty, J., Beyne, P. et al. (2005). Physiological modelling for indirect
evaluation of drug tissular pharmacokinetics under non-steady state conditions:an example of
antimicrobial prophylaxix during liver surgery J Pharmacokin Pharmacodyn 32(1): 1-23.
Laplanche, R., Meno-Tetang, G.M.L. y Kawai, R. (2007) Physiologically based
pharmacokinetic (PBPK) modelling of everolimus (RAD001) in rats involving non-linear tissue
uptake. J Pharmacokin Pharmacodyn 34(3): 373-399.
Lavé T., Coassolo P., y Reigner B. (1999). Prediction of Hepatic Metabolic Clearance
Based on Interspecies Allometric Scaling Techniques and In Vitro-In Vivo Correlations.
Clinical Pharmacokinetics 14: 211-231.
Lee, S. L.; et al. (2009) “In Vitro Considerations to Support Bioequivalence of Locally
Acting Drugs in Dry Powder Inhalers for Lung Diseases”. AAPS Journal 11(3): 414-423.
Lin, Y. J., y Schanker, L. S. (1981) Pulmonary absorption of amino acids in the rat:
evidence of carrier transport, Am J Physiol 240: C215-221.
Lindholm, A., Kahan, B.D. (1993). “Influence of cyclosporine pharmacokinetics, trough
concentrations, and AUC monitoring on outcome after kidney transplantation”. Clin Pharmacol
Ther, 54: 205-218.
Lipworth, B.J. (1996) “Pharmacokinetics of Inhaled Drugs”. Br. J. Clin. Pharmacol 42:
697-705.
Little, B.B. (1999). Pharmacokinetics During Pregnancy: Evidence-Based Maternal
Dose Formulation, Obstet Gynecol, 93: 858-68.
Liu, X.D. y Chen, J. (2001). Prediction of drug clearance in humans from laboratory
animals based on body surface area. European Journal of Drug Metabolism and
Pharmacokinetics 26: 249-256.
Loebstein, R., Koren, G. (2002). Clinical relevance of therapeutic drug monitoring
during pregnancy. Ther Drug Monit, 24:15-22.
Loeser, J.D., Butler, S.H., Chapman, C.R., Turk, D.C. (2001). Bonica’s Management of
Pain, 3ª ed. Lippincott Williams & Wilkins. Filadelfia.
Mahmood I. (2000). Can absolute oral bioavailability in humans be predicted from
animals: a comparison of allometry and different indirect methods. Drug Metabolism and Drug
Interactions 16: 143-155.
Mahmood, I. (2004). Interspecies scaling of Protein Drugs: Prediction of Clearance
from Animal to Humans. Journal of Pharmaceutical Sciences 93: 177-185.
Mahmood, I. (2006a). Prediction of Human Clearance from animal data: Application of
the Rule of Exponents and “Fu Corrected Intercept Method” (FCIM). Journal of
Pharmaceutical Sciences 95: 1810-1821.
Mahmood, I. (2006b). Prediction of Drug Clearance in children from adult. British
Journal of Clinical Pharmacology 61: 545-557.
5
TRATADO GENERAL DE BIOFARMACIA Y FARMACOCINÉTICA. VOLUMEN II
Mahmood, I., Balian, J.D. (1996). Interspecies scaling: Predicting Pharmacokinetic
Parameters of Antiepileptic Drugs in Humans from Animals with Special Emphasis on
Clearance. Journal of Pharmaceutical Sciences, 85: 411-414.
Mahmood, I., Balian, J.D. (1999). The Pharmacokinetic Principles Behind Scaling from
Preclinical Results to Phase I Protocols. Clinical Pharmacokinetics 14:1-11.
Mahmood, I., Sahajwalla, C. (2002). Interspecies Scaling of Biliary Excreted Drugs.
Journal of Pharmaceutical Sciences 8: 1908-1914.
Maitre, P.O., Buhrer, M., Thomson, D., Stanski, D.R. (1991). A three-step approach
combining Bayesian regresión and NONMEM population análisis: application to midazolam. J
Pharmacokin Biopharm 19: 377-38.
Maka, D.A., Murphy, L.K. (2000). “Drug nutrient interactions: a review”. AACN Clin
Issues, 11 (4): 580-589.
Mandema, J.W., Verotta, D., Sheiner, L.B. (1992). Building population
pharmacokinetic-pharmacodynamic models. I. Models for covariate effects. J Pharmacokin
Biopharm 20: 511-528.
Mason, G. R., Peters, A. M., Bagdades, E., Myers, M. J., Snooks, D. y Hughes, J. M. B.
(2001). Evaluation of pulmonary alveolar epithelial integrity by the detection of restriction to
diffusion of hydrophilic solutes of different molecular sizes, Clin Sci 100: 231-236 (2001).
Masuda, S., Goto, M., Okuda, M. et al. (2005) “Initial dosage adjustment for oral
administration of tacrolimus using the intestinal MDR1 level in living-donor liver transplant
recipients”. Transplant Proc, 37(4): 1728-1729.
Matsukawa, Y., Lee, V. H. L., Crandall, E. D. y Kim, K-J. (1997). Size-dependent
dextran transport across rat alveolar epithelial cell monolayers, J Pharm Sci 86: 305-309.
Matsukawa, Y., Yamahara, H., Yamashita, F., Lee, V. H., y Crandall, E. D. (2000).
Rates of protein transport across rat alveolar epithelial cell monolayers, J Drug Targeting 7:
335-342.
McCormack, J.P., Cooper, J., Carleton, B. (1997). Simple approach to dosage
adjustment in patients with renal impairment. Am J Health Syst Pharm, 54: 2505-9.
McLean, A.J., Le Couteur, D.G. (2004). Aging Biology and Geriatric Clinical
Pharmacology. Pharmacol Rev, 56: 163-84.
Mehendale, H. M., Angevine, L. S., y Ohmiya, Y. (1981). The isolated perfused lung –
A critical evaluation, Toxicology 21: 1-36.
Mehvar, R. (2001). “Principles of nonlinear pharmacokinetics”. American Journal of
pharmaceutical Education. 65: 178-84.
Mordenti, J. (1985). Forecasting Cephalosporin and Monobactam Antibiotic Half. Lives
in Humans from data Collected in Laboratory Animals. Antimicrobial Agents and
Chemotherapy 27: 887-891.
Mordenti, J. (1986). Man versus Beast: Pharmacokinetic Scaling in Mammals. J.
Pharm. Sci. 75:1028-1040.
Morimoto, K., Yamahara, H., Lee, V. H., y Kim, K. J. (1993). Dipeptide transport
across rat alveolar epithelial cell monolayers, Pharm Res 10: 1668-1674.
Murphy JE. (2008). Clinical Pharmacokinetics. 4th ed. American Society of HealthSystem Pharmacists. Bethesda.
N’Dri-Stempfer, B., Navidi, W.C., Guy, R.H., Bunge, A. (2008). Optimizing metrics for
the assessment of bioequivalence between topical drug products. Pharm Research, 25: 1621-9.
Nemmar, A., Hoet, P. H. M., Vanquickenborne, B., Dinsdale, D., Thomeer, M.,
Hoylaerts, M.F., Vanbilloen, H., Mortelmans, L., y Nemery, B. (2002) Passage of inhaled
particles into the blood circulation in humans, Circulation 105: 411-414.
Newhouse, M. T. (2006) “Drug Delivery: Pulmonary Delivery” en Encyclopedia of
Pharmaceutical Technology. Sawarbrick, J.; Editor. Informa Healthcare, 1(1): 1279 -166.
Niven, R. W. (1992). Modulated drug therapy with inhalation aerosols. En:
Pharmaceutical inhalation aerosol technology, Hickey, A. J., ed. (Chicago, Marcel Dekker, Inc),
págs. 321-359.
6
BIBLIOGRAFÍA
Nordberg, M., Duffus, J.H., Templeton, D.M. (2004) Glossary of terms used in
Toxicokinetics. (IUPAC Recommendations 2003). Pure Appl Chem 76(5): 1033-1082. 2004
IUPAC.
Obach R.S. y cols. (1997). The prediction of Human Pharmacokinetic Parameters from
Preclinical and In Vitro Metabolism Data. The Journal of Pharmacology and Experimental
Therapeutics 283: 46-58.
OECD Environment, Health and Safety publications. (2008). Guidance notes for the
estimation of dermal absorption values (draft) Mayo 2008.
Okamoto, H., Komatsu, H., Hashida, M., Sezaki, H. (1986) Effects of ß cyclodextrin
and di O methyl ß cyclodextrin on the percutaneous absorption ofbutylparaben, indomethacin
and sulfanilic acid. Int J Pharm 30: 35 45.
Padayatti S., Sun H., Wang, Y. et al. (2004). “Vitamin C pharmacokinetics: implication
for oral and intravenous use” Ann Intel Med, 140: 533-537.
Patrick, G., y Stirling, C. (1977). Measurement of mucociliary clearance from the
trachea of conscious and anaesthetisedrats, J Appl Physiol 42: 451-455.
Patton, J. S., McCabe, J. G., Hansen, S. E. y Daugherty, A. L. (l989-l990). “Absorption
of human growth hormone from the rat lung”. Biotechnol. Ther. 1: 213-28.
Pedraz J.L., Calvo B., Hernández R., Domínguez-Gil A. (1990). Extrapolación
farmacocinética entre diferentes especies animales y el hombre. Industria Farmacéutica NovDic: 65-78.
Petersson, K.J., Hanze, E., Savic, R.M., et al. (2009). Semiparametric distributions with
estimated shape parameters. Pharm Res. 26 (9): 2174-2185.
Poggesi, I., Benedetti, M.S., Whomsley, R. et al. (2009). Pharmacokinetics in special
populations. Drug Metab Rev, 41(3):422-54.
Potts, R.O., Francoeur, M.L. (1991) The influence of stratum corneum morphology on
water permeability. J. Invest Dermatol; 96:495-499.
Puigdemont, A., Ramis, J., Guitart, R., Arboix, M. (1993). Species Scaling of
Propafenone Disposition and Concentration-Time Relationships among Eight Mammalian
Species. Journal of Pharmaceutical Sciences 83: 1126-1129.
Revilla, N., Martín-Suárez, A., Pérez, M.P. et al. (2010). Vancomycin dosing
assessment in intensive care unit patients based on a population pharmacokinetic /
pharmacodynamic simulation. Br J Clin Pharmacol, 70(2):201-12.
Ritschel, W. (2004). Handbook of basic pharmacokinetics including clinical
applications. APHA.
Ritschel, W.A., Kearns, G.L. (2004). “Nonlinear Pharmacokinetics”. En: Ritschel,
W.A., Kearns, G.L; Handbook of Basic Pharmacokinetics: 6th ed., American Pharmaceutical
Association, Washington.
Riviere J.E. (1999). Interspecies Extrapolations. En: Comparative Pharmacokinetic
Principles, Techniques and Applications Iowa State University Press.
Rossi, S., Sandri, G, Caramella, C.M, (2005). “Buccal drug delivery: a challenge
already won?” Drug Discovery Today: Technologies 2(1): 59-64.
Rowland, M., Tozer, T.N. (1995). Clinical Pharmacokinetics: Concepts and
Applications, 3ª ed. Lea & Febiger. Malvern.
Rowland, M., Tozer, T.N (2010).”Dose and time dependencies”. En: Rowland, M. and
Tozer, T.N; Clinical Pharmacokinetics and Pharmacodynamics. Concepts and Applications.
4th ed., Lippincott Williams & Wilkins. Philadelphia.
Sakagami M., Byron P.R., Venitz J., Rypacek F. (2002) Solute disposition in the rat
lung in vivo and in vitro: determining regional absorption kinetics in the presence of
mucociliary escalator. J.Pharm. Sci. 91: 594-604.
Salt A.N., Plontke S.K.R. (2005) Local inner-ear drug delivery and pharmacokinetics.
Drug Discovery Today; 10(19): 1299-1306
Santos Ramos, B., Guerrero Aznar, D. (1994). Administración de medicamentos. Díaz
de Santos. Madrid.
Sarkar, M.A. (1992) “Drug metabolism in the Nasal Mucosa”. Pharm. Res. 9(1): 1-9.
7
TRATADO GENERAL DE BIOFARMACIA Y FARMACOCINÉTICA. VOLUMEN II
Schanker, L. S., y Burton, J. A. (1976) Absorption of heparin and cyanocobalamin from
the rat lung, Proc Soc Exp Biol Med 152: 377-380.
Schanker, L. S., y Hemberger, (1983). J. A. Relation between molecular weight and
pulmonary absorption rate of lipid-insoluble compounds in neonatal and adult rats, Biochem
Pharmacol 32: 2599-2601.
Schanker, L. S., Mitchell, E. W., y Brown, R. A., Jr. (1986).Species comparison of drug
absorption from the lung after aerosol inhalation or intratracheal injection, Drug Metab Dispos
14: 79-88.
Scheffer, G. L., Pijnenborg, A. C. L. M., Smit, E. F., Müller, M., Postma, D. S., Timens,
W.,van der Valk, P., de Vries, E. G. E., and Scheper, R. J. (2002). Multidrug resistance related
molecules in human and murine lung, J Clin Pathol 55: 332-339.
Schneeberger, E. E. (1991) Airway and alveolar epithelial cell junctions. In: The Lung:
Scientific Foundations, Crystal, R. G., y West, J. B., eds. (New York, Raven Press), pp. 205214.
Schneeberger, E. E. (1978). Structural basis for some permeability properties of the airblood barrier, Fed Proc 37: 2471-2478.
Schneeberger, E. E., y McCormack, J. M. (1984). Intercellular junctions in upper airway
submucosal glands of the rat: a tracer and freeze-fracture study., Anat Rec 210: 421-433.
Schnitzer, J. E. Caveolae (2001). From basic trafficking mechanisms to targeting
transcytosis for tissue-specific drug and gene delivery in vivo, Adv Drug Deliv Rev 49: 265-60.
Schoenwald, R. D. (1990) “Ocular Drug Delivery. Pharmacokinetic Considerations”.
Clin. Pharmacokinet.; 18(4): 255.
Schulz M, Schmoldt A. (2003) Therapeutic and toxic blood concentrations of more than
800 drugs and other xenobiotics Pharmazie. Jul; 58(7):447-74.
Senel, S. y Hincal, A. A. (2001). “Drug permeation enhancement via buccal route:
possibilities and limitations.” J Control Release 72(1-3): 133-44.
Shargel, L., Wu-Pong, S. y Yu, A.B.C. (2005). Applied Biopharmaceutics and
Pharmacokinetics. Mc Graw-Hill. New York.
Shargel, L., Wu-Pong, S., Yu, A.B.C. (2005). Applied Biopharmaceutics and
Pharmacokinetics, 5ª ed. The McGraw-Hill Companies, Inc. New Baskerville.
Sharma, S., Mukkur, T.K.S., Benson, H.A.E., Chen, Y. (2009) Pharmaceutical aspects
of intranasal delivery of vaccines using particulate systems. J. Pharmaceutical Science; 98(3):
812-843.
Sheiner, L.B., Beal, S.L. (1981). Evaluation of methods for estimating population
pharmacokinetic parameters.II. Biexponential model and experimental pharmacokinetic data. J
Pharmacokinet Biopharm, 9: 635-651.
Sheiner, L.B., Rosenberg, B., Marathe, V. (1977). Estimation of population
characteristics of pharmacokinetic parameters from routine clinical data. J Pharmacokinet
Biopharm, 5: 445-479.
Simon, G.A., Maibach, H.I. (2000). The pig as an experimental animal model of
percutaneous permeation in man: qualitative and quantitative observations- An Overview. Skin
Pharmacol App Skin Physiol; 13: 229-34.
Sinha, V.K., De Buick, S. et al. (2008). Predicting Oral Clearance in Humans How
close Can We Get with Allometry? Clinical Pharmacokinetics 47: 35-45.
Sirot, E.V., Van der Velden, J.W., Rentch, K. et al. (2006). Therapeutic drug
monitoring and pharmacogenetic tests as tools in pharmacovigilance. Drug Safety, 29:735-68.
Skelly, J.P., Shah, V.P., Maibach, H.I., Guy, R.H., Wester, R.C., Flynn, G., Yacobi, A.
(1987) FDA and AAPS report of the workshop on principles and practices of in vitro
percutaneous penetration studies: relevance to bioavailability and bioequivalence. Pharm
Research, 4 (3): 45-7.
Slutter, B., Hagenaars, N., Jiskoot, W. (2008) Rational design of nasal vaccines. Journal
of Drug Targeting. 16(1): 1-17.
Squier, C. A. (1991). “The permeability of oral mucosa”. Critical Reviews in Oral
Biology and Medicine 2(1): 13-32.
8
BIBLIOGRAFÍA
Sudhakar, Y., Kuotsu, K. y Bandyopadhyay, A. K. (2006). “Buccal bioadhesive drug
delivery-a promising option for orally less efficient drugs”. J Control Release 114(1): 15-40.
Takenaka, S., Karg, E., Roth, C., Schulz, H., Ziesenis, A., Heinzmann, U., Schramel, P.,
y Heyder, J. (2001) Pulmonary and systemic distribution of inhaled ultrafine silver particles in
rats, Environ Health Perspect 109: 547-551.
Tang, H. y Mayersohn, M. (2005). Accuracy of allometrically predicted
pharmacokinetic parameters in humans: role of species selection. Drug Metabolism and
Disposition 33: 1288-1293.
Tang, H. y Mayersohn, M. (2006). A Global Examination of Allometric Scaling for
Predicting Human Drug Clearance and the prediction of Large Vertical Allometry. Journal of
Pharmaceutical Sciences 95: 1783-1799.
Taylor, G. (1990) The absorption and metabolism of xenobiotics in the lung, Adv Drug
Deliv Rev 5: 37-61.
Taylor, M.J., Diers Caviness, M. (1986) A textbook for the clinical applications of
therapeutic drug monitoring. Abbott Laboratories. Diagnostics Division. Texas.
Teorell T. (1937) Kinetics of Distribution of Substances Administered to the Body.
Arch Intern Pharmacodyn 57: 202-225
Tour, J.D., Neef, C., Thomson, A.H. et al. (2007) Cost-effectiveness of therapeutic drug
monitoring: an update. The European Journal of Hospital Pharmacy Science. 13. 83-91.
Tozer, T. N. y Rowland, M. (2006). Introduction to Pharmacokinetics and
Pharmacodynamics: the Quantitative Basis of Drug Therapy Lippincott Williams & Wilkins.
New York
Trocóniz, I.F., Tillmann, C., Liesenfeld, K.H., Schäfer, H.G., Stangier, J. (2007).
Population pharmacokinetic analysis of the new oral thrombin inhibitor dabigatran etexilate
(BIBR 1048) in patients undergoing primary elective total hip replacement surgery. J Clin
Pharmacol 47: 371-382.
Tronde, A., Krondahl, E., von Euler-Chelpin, H., Brunmark, P., Hultkvist Bengtsson,
U., Ekström, G., y Lennernäs, H. (2002) High airway-to-blood transport of an opioid
tetrapeptide in the isolated rat lung after aerosol delivery, Peptides 23: 469-478.
U.S. Department of Health and Human Services, Food and Drug Administration.
(1999). Guidance for Industry. Population Pharmacokinetics. URL:
http://www.fda.gov/cder/guidance/
Varghese, J.M., Roberts, J.A., Lipman, J. (2010). Pharmacokinetics and
pharmacodynamics in critically ill patients. Curr Opin Anaesthesiol. 23(4): 472-8.
Wählby, U., Thomson, A.H., Milligan, P.A. et al. (2004). Models for time-varying
covariates in population pharmacokinetic-pharmacodynamic analysis. Br J Clin Pharmacol
58(4): 367-377.
Wan, H., Winton, H. L., Soeller, C., Stewart, G. A., Thompson, P. J., Gruenert, D. C.,
Cannell, M. B., Garrod, D. R., y Robinson, C. (2000). Tight junction properties of the
immortalized human bronchial epithelial cell lines Calu-3 and 16HBE14o-, Eur Respir J 15,
1058-1068.
Ward, K.W. y Smith, B.R. (2004). A comprehensive quantitative and qualitative
evaluation of extrapolation of intravenous pharmacokinetic parameters from rat, dog and
monkey to humans. I. Clearance. Drug Metabolism and Disposition 32: 603-611.
Weiss M. 2007. Mechanistic modeling of digoxin distribution kinetics incorporating
slow tissue binding. Eur J Pharm Sci 30: 256-263.
West G.B., Brown J.H., Enquist B.J. (1999). The Fourth Dimension of Life: Fractal
Geometry and Allometric Scaling of Organisms. Science 284: 1677-1679.
Willmann, S., Hóhn, K., y Edginton, A. (2007) Development of a physiology-based
whole-body population model for assessing the influence of individual variability on the
pharmacokinetics of drugs. J Pharmacokin Pharmacodyn 34 (3): 401-431.
Wilson, C. G.; Washington, N. (1989) “Physilogical Pharmaceutics. Biological Barriers
to Drug Absorption” En Ellis Horwood Series in Pharmaceutical Technology. Ellis Horwood.
Chichester.
9
TRATADO GENERAL DE BIOFARMACIA Y FARMACOCINÉTICA. VOLUMEN II
Wilson, C.G. y Washington, N. (1989) “Physiological Pharmaceutics. Biological
barriers to drug absorption”. En Ellis Horwood Series in Pharmaceutical Technology.
Inglaterra, 1989.
Wiltshire, H., C. V. Paya, M. D. Pescovitz, A. Humar, E. Dominguez, K. Washburn, E.
Blumberg, B. Alexander, R. Freeman, N. Heaton, y K. P. Zuideveld. (2005).
Pharmacodynamics of oral ganciclovir and valganciclovir in solid organ transplant recipients.
Transplantation 79: 1477-1483.
Winfield, A.J., Richards, R.M.E. (2003). Pharmaceutical Practice, 3ª ed. Churchill
Livingstone. Londres.
Winkler, J.; Hochhaus, G.; y Derendorf, H. (2004). “How the Lungs Handles Drugs:
Pharmacokinetics and Pharmacodynamics of Corticosteroids”. Proc. Am. Thorac. Soc. 1: 356–
363.
Xu L., Eiseman J.L., Egorin M.J. et al. (2003). Physiologically based pharmacokinetics
and molecular pharmacodynamics of 17-(allylamino)-17-demethoxygeldanamycin and its active
metabolite in tumor-bearing mice. J Pharmacokin Pharmacodyn 30: 185-201.
Yamashita, F., Kim, K. J., y Lee, V. H. L. (1998). Dipeptide uptake and transport
characteristics in rabbit tracheal epithelial cell layers cultured at an air interface, Pharm Res 15:
979-983.
10